198 related articles for article (PubMed ID: 17074266)
41. Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summary.
Lee YV; Wahab HA; Choong YS
Biomed Res Int; 2015; 2015():895453. PubMed ID: 25649791
[TBL] [Abstract][Full Text] [Related]
42. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence.
Muñoz-Elías EJ; McKinney JD
Nat Med; 2005 Jun; 11(6):638-44. PubMed ID: 15895072
[TBL] [Abstract][Full Text] [Related]
43. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
[TBL] [Abstract][Full Text] [Related]
44. Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis.
Dosso M; Ouattara L; Cherif AM; Bouzid SA; Haller L; Fernex M
Chemotherapy; 2001; 47(2):123-7. PubMed ID: 11173814
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of efflux pump genes of Mycobacterium tuberculosis in response to varied subinhibitory concentrations of antituberculosis agents.
Garima K; Pathak R; Tandon R; Rathor N; Sinha R; Bose M; Varma-Basil M
Tuberculosis (Edinb); 2015 Mar; 95(2):155-61. PubMed ID: 25680943
[TBL] [Abstract][Full Text] [Related]
46. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase.
Krátký M; Vinšová J; Novotná E; Mandíková J; Wsól V; Trejtnar F; Ulmann V; Stolaříková J; Fernandes S; Bhat S; Liu JO
Tuberculosis (Edinb); 2012 Sep; 92(5):434-9. PubMed ID: 22765970
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
Rao M; Valentini D; Zumla A; Maeurer M
Int J Infect Dis; 2018 Apr; 69():78-84. PubMed ID: 29501835
[TBL] [Abstract][Full Text] [Related]
48. ¹³C metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation.
Beste DJ; Bonde B; Hawkins N; Ward JL; Beale MH; Noack S; Nöh K; Kruger NJ; Ratcliffe RG; McFadden J
PLoS Pathog; 2011 Jul; 7(7):e1002091. PubMed ID: 21814509
[TBL] [Abstract][Full Text] [Related]
49. Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins.
Bardou F; Quémard A; Dupont MA; Horn C; Marchal G; Daffé M
Antimicrob Agents Chemother; 1996 Nov; 40(11):2459-67. PubMed ID: 8913447
[TBL] [Abstract][Full Text] [Related]
50. Targeting isocitrate lyase for the treatment of latent tuberculosis.
Bhusal RP; Bashiri G; Kwai BXC; Sperry J; Leung IKH
Drug Discov Today; 2017 Jul; 22(7):1008-1016. PubMed ID: 28458043
[TBL] [Abstract][Full Text] [Related]
51. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis.
Argyrou A; Jin L; Siconilfi-Baez L; Angeletti RH; Blanchard JS
Biochemistry; 2006 Nov; 45(47):13947-53. PubMed ID: 17115689
[TBL] [Abstract][Full Text] [Related]
52. Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor.
Sriram D; Yogeeswari P; Methuku S; Vyas DR; Senthilkumar P; Alvala M; Jeankumar VU
Bioorg Med Chem Lett; 2011 Sep; 21(18):5149-54. PubMed ID: 21840711
[TBL] [Abstract][Full Text] [Related]
53. Demystifying the catalytic pathway of Mycobacterium tuberculosis isocitrate lyase.
Ibeji CU; Salleh NAM; Sum JS; Ch'ng ACW; Lim TS; Choong YS
Sci Rep; 2020 Nov; 10(1):18925. PubMed ID: 33144641
[TBL] [Abstract][Full Text] [Related]
54. Isoniazid-induced control of Mycobacterium tuberculosis by primary human cells requires interleukin-1 receptor and tumor necrosis factor.
Yamashiro LH; Eto C; Soncini M; Horewicz V; Garcia M; Schlindwein AD; Grisard EC; Rovaris DB; Báfica A
Eur J Immunol; 2016 Aug; 46(8):1936-47. PubMed ID: 27230303
[TBL] [Abstract][Full Text] [Related]
55. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice.
Dhar N; McKinney JD
Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12275-80. PubMed ID: 20566858
[TBL] [Abstract][Full Text] [Related]
56. Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria.
Leidinger P; Treptow J; Hagens K; Eich J; Zehethofer N; Schwudke D; Oehlmann W; Lünsdorf H; Goldmann O; Schaible UE; Dittmar KE; Feldmann C
Angew Chem Int Ed Engl; 2015 Oct; 54(43):12597-601. PubMed ID: 26332072
[TBL] [Abstract][Full Text] [Related]
57. Active Site Flexibility of Mycobacterium tuberculosis Isocitrate Lyase in Dimer Form.
Lee YV; Choi SB; Wahab HA; Choong YS
J Chem Inf Model; 2017 Sep; 57(9):2351-2357. PubMed ID: 28820943
[TBL] [Abstract][Full Text] [Related]
58. Susceptibility of Mycobacterium tuberculosis to isoniazid and its derivative, 1-isonicotinyl-2-nonanoyl hydrazine: investigation at cellular level.
Mohamad S; Ibrahim P; Sadikun A
Tuberculosis (Edinb); 2004; 84(1-2):56-62. PubMed ID: 14670346
[TBL] [Abstract][Full Text] [Related]
59. Microbiology. A weak link in TB bacterium is found.
Helmuth L
Science; 2000 Aug; 289(5482):1123-5. PubMed ID: 10970221
[TBL] [Abstract][Full Text] [Related]
60. Polyclonal antibody against conserved sequences of mce1A protein blocks MTB infection in macrophages.
Sivagnanam S; Namasivayam N; Chellam R
Appl Microbiol Biotechnol; 2012 Mar; 93(6):2463-73. PubMed ID: 22159737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
